Market News AIOpen the app

Biogen and Eisai shared new three-year results showing LEQEMBI helps early Alzheimer's patients by slowing dementia progression by 76%.

TrialRead the original at investors.biogen.com
Good for BIIB

Biogen's LEQEMBI study found slower progression than in a matched natural history group, and most patients stayed on treatment. No new safety signals appeared during subcutaneous maintenance, supporting long-term use, though the comparison does not prove the same result for every patient.

BIIB · Biogen

AI read · Good for BIIB

The AI's read

These findings add support for LEQEMBI's long-term use in early Alzheimer's disease. Continued treatment by most patients and no new safety signals during subcutaneous maintenance strengthen that case. The comparison used a matched natural history group, so it does not prove the same result for every patient.

Get alerts for BIIB

Follow Biogen (BIIB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BIIB
Free on the App Store and Google Play, or on the web.